Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 17747
Country/Region: Nigeria
Year: 2014
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $5,498,031 Additional Pipeline Funding: $5,033,285

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The Henry Jackson Foundation and its local body, HJFMRI, partners with NMOD-EPIC to strengthen HIV services in 46 military health facilities serving both military personnel and civilians in 19 states and the FCT. To enhance efficiency, HJF will institute results-based program management (RBM) strategy in COP 14/15 to reduce the cost per achievement. It will also identify and exploit areas of synergy between the different technical areas through joint site supportive supervisory visits and use of mentors based at nearby sites. Efforts will be stepped up to strengthen the Hub and Spoke model. In FY13, HJF and EPIC implemented joint program planning, execution and monitoring of activities at the sites, which helped to increase NMOD’s technical capacity, continuing to transition responsibility and ownership of the program. This joint program management will be further strengthened in COP 14/15. In addition, the NMOD currently provides approximately 30 - 50% of all the funds used to run the program. In COP 14/15, progressively more financial responsibility for the program will be transitioned to the NMOD. Activities in COP 14 and 15, as in the previous years, will be monitored through periodic site visits. In addition, process and outcome evaluations will be built into every activity. Implementation science will be scaled up in COP 14 and 15 with a clearly outlined mechanism of feeding back into the program. All of these will be facilitated through the effective implementation of the RBM strategy. With improved effectiveness in implementation as a result of the introduction of RBM, we anticipate being able to do more within a static budget envelope.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $613,582
Care: TB/HIV (HVTB) $140,734
Care: Pediatric Care and Support (PDCS) $42,399
Laboratory Infrastructure (HLAB) $1,105,717
Strategic Information (HVSI) $375,291
Health Systems Strengthening (OHSS) $297,461
Biomedical Prevention: Blood Safety (HMBL) $7,879
Biomedical Prevention: Injection Safety (HMIN) $12,866
Sexual Prevention: Abstinence/Be Faithful (HVAB) $118,405
Testing: HIV Testing and Counseling (HVCT) $158,625
Sexual Prevention: Other Sexual Prevention (HVOP) $199,125
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $390,612
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,914,874
Treatment: Pediatric Treatment (PDTX) $120,461
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory 2015 163
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV 2015 33
BS_COLL Number of whole blood collections each year by the NBTS ne2rk 2015 163
FPINT_SITE By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 14
FPINT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points 2015 14
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 14
FPINT_SITE Service delivery type: Clinical 2015 14
FPINT_SITE Sum of Numerator Site Support Type disaggregates 2015 14
FPINT_SITE Sum of Service Delivery Type disaggregates 2015 14
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2015 14
FPINT_SITE_den Sum of Denominator Site Support Type disaggregates 2015 14
GEND_GBV Age: 0-9 2015 2
GEND_GBV Age: 10-14 2015 4
GEND_GBV Age: 15-17 2015 6
GEND_GBV Age: 18-24 2015 3
GEND_GBV Age: 25+ 2015 2
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 13
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 4
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 13
GEND_GBV Number of people receiving post-GBV care 2015 17
GEND_GBV Sex: Female 2015 11
GEND_GBV Sex: Male 2015 6
GEND_GBV Sum of Age disaggregates 2015 17
GEND_GBV Sum of Sex disaggregates 2015 17
HTS_TST Age/sex: <1 Female 2015 639
HTS_TST Age/sex: <1 Female 2015 639
HTS_TST Age/sex: <1 Male 2015 614
HTS_TST Age/sex: <1 Male 2015 614
HTS_TST Age/sex: 1-4 Female 2015 913
HTS_TST Age/sex: 1-4 Female 2015 913
HTS_TST Age/sex: 1-4 Male 2015 877
HTS_TST Age/sex: 1-4 Male 2015 877
HTS_TST Age/sex: 10-14 Female 2015 821
HTS_TST Age/sex: 10-14 Female 2015 821
HTS_TST Age/sex: 10-14 Male 2015 789
HTS_TST Age/sex: 10-14 Male 2015 789
HTS_TST Age/sex: 15-19 Female 2015 9,127
HTS_TST Age/sex: 15-19 Female 2015 9,127
HTS_TST Age/sex: 15-19 Male 2015 8,769
HTS_TST Age/sex: 15-19 Male 2015 8,769
HTS_TST Age/sex: 20-24 Female 2015 18,253
HTS_TST Age/sex: 20-24 Female 2015 18,253
HTS_TST Age/sex: 20-24 Male 2015 17,537
HTS_TST Age/sex: 20-24 Male 2015 17,537
HTS_TST Age/sex: 25-49 Female 2015 59,323
HTS_TST Age/sex: 25-49 Female 2015 59,323
HTS_TST Age/sex: 25-49 Male 2015 56,997
HTS_TST Age/sex: 25-49 Male 2015 56,997
HTS_TST Age/sex: 5-9 Female 2015 365
HTS_TST Age/sex: 5-9 Female 2015 365
HTS_TST Age/sex: 5-9 Male 2015 351
HTS_TST Age/sex: 5-9 Male 2015 351
HTS_TST Age/sex: 50+ Female 2015 1,825
HTS_TST Age/sex: 50+ Female 2015 1,825
HTS_TST Age/sex: 50+ Male 2015 1,754
HTS_TST Age/sex: 50+ Male 2015 1,754
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,738
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,631
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 88,528
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 85,057
HTS_TST Aggregated Age/sex: <15 Female 2015 2,738
HTS_TST Aggregated Age/sex: <15 Male 2015 2,631
HTS_TST Aggregated Age/sex: 15+ Female 2015 88,528
HTS_TST Aggregated Age/sex: 15+ Male 2015 85,057
HTS_TST By Test Result: Negative 2015 5,369
HTS_TST By Test Result: Negative 2015 173,585
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 178,954
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 178,954
HTS_TST Sum of Age/Sex disaggregates 2015 178,954
HTS_TST Sum of Age/Sex disaggregates 2015 178,954
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,369
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,369
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 173,585
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 173,585
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 178,954
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 178,954
HTS_TST Sum of Test Result disaggregates 2015 178,954
HTS_TST Sum of Test Result disaggregates 2015 178,954
HTS_TST_POS By Test Result: Positive 2015 173,585
HTS_TST_POS By Test Result: Positive 2015 5,369
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 2,469
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 11
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 42
KP_PREV By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 133
KP_PREV By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 13
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 2,655
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 5
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 5
LAB_ACC Sum of Support Type disaggregates 2015 5
LAB_CAP By clinical laboratories 2015 26
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 26
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 26
LAB_CAP Sum of Site Support Type disaggregates 2015 26
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 21
LAB_PT CD4: Number of laboratories that participate in this PT program 2015 26
LAB_PT CD4: Number of laboratories that perform this testing 2015 26
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 2
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2015 2
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2015 2
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 21
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2015 26
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2015 26
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 3
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2015 3
LAB_PT HIV viral load: Number of laboratories that perform this testing 2015 3
LAB_PT Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program 2015 26
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 36
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program 2015 45
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing 2015 45
PMTCT_ARV Life-long ART (including Option B+) 2015 648
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 59
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 472
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,296
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,179
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 428
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 220
PMTCT_ARV Sum of New and Current disaggregates 2015 648
PMTCT_ARV Sum of Regimen Type disaggregates 2015 1,179
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 648
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 59
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 472
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 1,296
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 1,179
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 428
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 220
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 648
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 1,179
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 389
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 790
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 59
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 1,340
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 1,179
PMTCT_EID Sum of Infant Age disaggregates 2015 1,179
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 41
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 49
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 41
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 41
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 49
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 49
PMTCT_STAT By: Known positives at entry 2015 518
PMTCT_STAT By: Number of new positives identified 2015 778
PMTCT_STAT Number of new ANC and L&D clients 2015 17,265
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 15,711
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,296
PMTCT_STAT_NGI By: Known positives at entry 2015 628
PMTCT_STAT_NGI By: Number of new positives identified 2015 941
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 17,265
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 15,711
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,569
PP_PREV Age/sex: 10-14 Female 2015 1,615
PP_PREV Age/sex: 10-14 Male 2015 1,552
PP_PREV Age/sex: 15-19 Female 2015 1,938
PP_PREV Age/sex: 15-19 Male 2015 1,862
PP_PREV Age/sex: 20-24 Female 2015 4,845
PP_PREV Age/sex: 20-24 Male 2015 4,655
PP_PREV Age/sex: 25-49 Female 2015 7,268
PP_PREV Age/sex: 25-49 Male 2015 6,982
PP_PREV Age/sex: 50+ Female 2015 485
PP_PREV Age/sex: 50+ Male 2015 465
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 31,667
PP_PREV Sum of Age/Sex disaggregates 2015 31,667
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 23
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 27
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 23
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 23
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 27
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 27
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 27
SITE_SUPP By program area/support type: General Population Prevention Direct Service Delivery (DSD) 2015 49
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 49
SITE_SUPP By program area/support type: Key Populations Prevention Direct Service Delivery (DSD) 2015 49
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 26
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) 2015 14
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 49
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 45
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 27
SITE_SUPP Number of unique sites supported by PEPFAR 2015 49
TX_CURR Age/Sex: <1 Female 2015 29
TX_CURR Age/Sex: <1 Male 2015 33
TX_CURR Age/Sex: 1-4 Female 2015 138
TX_CURR Age/Sex: 1-4 Male 2015 155
TX_CURR Age/Sex: 15+ Female 2015 17,076
TX_CURR Age/Sex: 15+ Male 2015 8,411
TX_CURR Age/Sex: 5-14 Female 2015 251
TX_CURR Age/Sex: 5-14 Male 2015 283
TX_CURR Aggregated Age/Sex: <1 Female 2015 29
TX_CURR Aggregated Age/Sex: <1 Male 2015 33
TX_CURR Aggregated Age/Sex: <15 Female 2015 418
TX_CURR Aggregated Age/Sex: <15 Male 2015 471
TX_CURR Aggregated Age/Sex: 15+ Female 2015 17,076
TX_CURR Aggregated Age/Sex: 15+ Male 2015 8,411
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 26,376
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 1
TX_CURR Sum of age/sex disaggregates 2015 889
TX_CURR Sum of Aggregated Age/Sex <15 2015 889
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 25,487
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 26,376
TX_CURR_NGI Age/Sex: <1 Female 2015 29
TX_CURR_NGI Age/Sex: <1 Male 2015 33
TX_CURR_NGI Age/Sex: 1-4 Female 2015 138
TX_CURR_NGI Age/Sex: 1-4 Male 2015 155
TX_CURR_NGI Age/Sex: 15+ Female 2015 17,076
TX_CURR_NGI Age/Sex: 15+ Male 2015 8,411
TX_CURR_NGI Age/Sex: 5-14 Female 2015 251
TX_CURR_NGI Age/Sex: 5-14 Male 2015 283
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 29
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 33
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 418
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 471
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 17,076
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 8,411
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 26,376
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 26,376
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 889
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 25,487
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 26,376
TX_NEW Aggregated Grouping by Age: <1 Male 2015 16
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 16
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 103
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 117
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 4,355
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 1,956
TX_NEW Breastfeeding status 2015 216
TX_NEW By Age/Sex: <1 Female 2015 16
TX_NEW By Age/Sex: <1 Male 2015 16
TX_NEW By Age/Sex: 1-4 Female 2015 21
TX_NEW By Age/Sex: 1-4 Male 2015 23
TX_NEW By Age/Sex: 10-14 Female 2015 41
TX_NEW By Age/Sex: 10-14 Male 2015 48
TX_NEW By Age/Sex: 15-19 Female 2015 653
TX_NEW By Age/Sex: 15-19 Male 2015 293
TX_NEW By Age/Sex: 20-24 Female 2015 1,089
TX_NEW By Age/Sex: 20-24 Male 2015 489
TX_NEW By Age/Sex: 25-49 Female 2015 1,742
TX_NEW By Age/Sex: 25-49 Male 2015 783
TX_NEW By Age/Sex: 5-9 Female 2015 26
TX_NEW By Age/Sex: 5-9 Male 2015 29
TX_NEW By Age/Sex: 50+ Female 2015 871
TX_NEW By Age/Sex: 50+ Male 2015 391
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 6,531
TX_NEW Pregnancy status 2015 348
TX_NEW Sum of Age/Sex disaggregates 2015 6,531
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 6,531
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 138
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 6,547
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 207
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 345
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 6,547
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 6,892
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 3,239
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 8,108
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 162
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 7,703
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 243
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 405
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 7,703
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 381
Cross Cutting Budget Categories and Known Amounts Total: $3,450,000
Human Resources for Health $2,500,000
Gender: Gender Based Violence (GBV) $150,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $300,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Key Populations: MSM and TG $500,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Military Populations
Tuberculosis
Family Planning